Antifibrotic effect of synthetic Smad/Sp1 chimeric decoy oligodeoxynucleotide through the regulation of epithelial mesenchymal transition in unilateral ureteral obstruction model of mice

Akagi, 1996, Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis, Kidney International, 50, 148, 10.1038/ki.1996.297 Blobe, 2000, Role of transforming growth factor beta in human disease, The New England Journal of Medicine, 342, 1350, 10.1056/NEJM200005043421807 Border, 1990, Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1, Nature, 346, 371, 10.1038/346371a0 Böttinger, 2002, TGF-β signaling in renal disease, Journal of the American Society of Nephrology, 13, 2600, 10.1097/01.ASN.0000033611.79556.AE Chae, 2006, Ring-Sp1 decoy oligonucleotide effectively suppresses extracellular matrix gene expression and fibrosis of rat kidney induced by unilateral ureteral obstruction, Gene Therapy, 13, 430, 10.1038/sj.gt.3302696 Chu, 2005, Sp1: regulation of gene expression by phosphorylation, Gene, 348, 1, 10.1016/j.gene.2005.01.013 Datta, 2000, Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-beta -induced physical and functional interactions between smads and Sp1, Journal of Biological Chemistry, 274, 40014, 10.1074/jbc.C000508200 Dave, 2003, RNA interference: on the road to an alternate therapeutic strategy!, Reviews in Medical Virology, 13, 373, 10.1002/rmv.407 Feng, 2005, Specificity and versatility in TGF-β1 signaling through Smads, Annual Review of Cell and Developmental Biology, 21, 659, 10.1146/annurev.cellbio.21.022404.142018 Flanders, 2004, Smad3 as a mediator of the fibrotic response, International Journal of Experimental Pathology, 85, 47, 10.1111/j.0959-9673.2004.00377.x Geiser, 1993, Regulation of the transforming growth factor-beta 1 and -beta 3 promoters by transcription factor Sp1, Gene, 129, 223, 10.1016/0378-1119(93)90272-5 Hudson, 2003, Alport's syndrome, Goodpasture's syndrome, and type IV collagen, The New England Journal of Medicine, 348, 2543, 10.1056/NEJMra022296 Isaka, 1993, Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney, The Journal of Clinical Investigation, 92, 2597, 10.1172/JCI116874 Ishibashi, 2000, Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities, Cancer Research, 60, 6531 Iwano, 2002, Evidence that fibroblasts derive from epithelium during tissue fibrosis, The Journal of Clinical Investigation, 110, 341, 10.1172/JCI0215518 Kalluri, 2003, Epithelial–mesenchymal transition and its implications for fibrosis, The Journal of Clinical Investigation, 112, 1776, 10.1172/JCI200320530 Kawauchi, 2000, Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates, Circulation Research, 87, 1063, 10.1161/01.RES.87.11.1063 Kim, 1998, Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury, Journal of Biological Chemistry, 273, 33750, 10.1074/jbc.273.50.33750 Kim, 2009, Transcriptional regulation of NF-kappaB by ring type decoy oligodeoxynucleotide in an animal model of nephropathy, Experimental and Molecular Pathology, 86, 114, 10.1016/j.yexmp.2008.11.011 Latchman, 1997, Transcription factors: an overview, The International Journal of Biochemistry & Cell Biology, 29, 1305, 10.1016/S1357-2725(97)00085-X Liu, 2004, Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention, Journal of the American Society of Nephrology, 15, 1, 10.1097/01.ASN.0000106015.29070.E7 Maeshima, 1998, Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo, The Journal of Clinical Investigation, 101, 2589, 10.1172/JCI429 Magae, 1993, Effects of microbial products on glucose consumption and morphology of macrophages, Bioscience, Biotechnology, and Biochemistry, 57, 1628, 10.1271/bbb.57.1628 Miyazono, 2000, TGF-β signaling by Smad proteins, Advances in Immunology, 75, 115, 10.1016/S0065-2776(00)75003-6 Morishita, 1997, In vivo transfection of cis element “decoy” against nuclear factor-kappaB binding site prevents myocardial infarction, Nature Medicine, 3, 894, 10.1038/nm0897-894 Nehls, 1993, Mithramycin selectively inhibits collagen-alpha 1(I) gene expression in human fibroblast, The Journal of Clinical Investigation, 92, 2916, 10.1172/JCI116914 Ng, 1998, Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats, Kidney International, 54, 864, 10.1046/j.1523-1755.1998.00076.x Park, 2009, Antifibrotic effect through the regulation of transcription factor using ring type-Sp1 decoy oligodeoxynucleotide in carbon tetrachloride-induced liver fibrosis, The Journal of Gene Medicine, 11, 824, 10.1002/jgm.1355 Poncelet, 2001, Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells, Journal of Biological Chemistry, 276, 6983, 10.1074/jbc.M006442200 Rastaldi, 2002, Epithelial–mesenchymal transition of tubular epithelial cells in human renal biopsies, Kidney International, 62, 137, 10.1046/j.1523-1755.2002.00430.x Remuzzi, 1998, Pathophysiology of progressive nephropathies, The New England Journal of Medicine, 339, 1448, 10.1056/NEJM199811123392007 Roberts, 2006, Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis, Cytokine & Growth Factor Reviews, 17, 19, 10.1016/j.cytogfr.2005.09.008 Slansky, 1993, A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter, Molecular Cell Biology, 13, 1610, 10.1128/MCB.13.3.1610 Takabatake, 2005, Exploring RNA interference as a therapeutic strategy for renal disease, Gene Therapy, 12, 965, 10.1038/sj.gt.3302480 Verrecchia, 2001, Blocking sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis, The Journal of Investigative Dermatology, 116, 755, 10.1046/j.1523-1747.2001.01326.x Yamashita, 1998, Identification of cis-elements of the human endothelin-A receptor gene and inhibition of the gene expression by the decoy strategy, Journal of Biological Chemistry, 273, 15993, 10.1074/jbc.273.26.15993 Zeisberg, 2004, The role of epithelial-to-mesenchymal transition in renal fibrosis, Journal of Molecular Medicine, 82, 175, 10.1007/s00109-003-0517-9 Zeisberg, 2001, Renal fibrosis: an update, Current Opinion in Nephrology and Hypertension, 10, 315, 10.1097/00041552-200105000-00004 Zeisberg, 2003, BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury, Nature Medicine, 9, 964, 10.1038/nm888 Zhang, 2003, Sp1 and Sp3 transcription factors synergistically regulate HGF receptor gene expression in kidney, American Journal of Physiology. Renal Physiology, 284, F82, 10.1152/ajprenal.00200.2002